

Bomi Italia S.p.A.

– PRESS RELEASE –

Completion of the acquisition of De Salute S.r.l.

Vaprio d'Adda, 23 January 2018 - Bomi Italia S.p.A. ("**Bomi**" or the "**Company**" or the "**Issuer**") the parent company of Bomi Group, a market leader in the biomedical logistics sector and the management of high technology healthcare products, which is listed on the multilateral trading system of **AIM Italia / Alternative Investment Market**, following the Press Release of 6 December 2017, announces that it has today completed the acquisition of 100% of the share capital of "**De Salute S.r.l.**" ("**De Salute**"), a company which operates in the pharmaceutical logistics and services sector (biotech and generic) located in Soresina (Cremona).

This acquisition, concluded for a consideration of Euro 2,450,000, plus an earn-out component (up to a maximum additional Euro 1,600,000) tied to the achievement of specific performance parameters to be calculated by 31 March 2019, represents a continuation of Bomi Group's strategy of consolidation in Europe, and extends the provision of its services to a market that offers prospects to increase added value and which also presents the Group with significant transportation synergies and further potential for cross-selling.

According to management estimates, De Salute is expected to have generated revenues in 2017 of about Euro 10.4 million with an Ebitda margin (in accordance with Group IAS principles) of about 13% and an Adjusted Net Financial Position* (in accordance with Group IAS principles) of about Euro 2.3 million.

Bomi Italia S.p.A. is the Parent Company of Bomi Group, a world leader in the biomedical logistics sector and in the management of high technology healthcare products. It was one of the first companies to receive the "Elite" certificate issued by Borsa Italiana.

Bomi Group's activities are concentrated in the integrated logistics sector and offer a wide range of logistics services in outsourcing to companies operating in the healthcare sector, managing distribution of medical equipment, pharmaceuticals, in-vitro diagnostic equipment, reagents and implant products.

Bomi Group's portfolio of about 100 clients includes some of the world's top healthcare companies (such as the leading pharmaceutical companies and producers of healthcare devices) as well as small and medium sized companies operating at a global level in the biomedical, diagnostics and biotech industries.

Bomi Group currently has about 1,080 employees and operates through subsidiary companies and associated companies in Europe, South America, China and the United States and its services are also provided, through strategic alliances with local partners.

ISIN Ordinary Share Code: IT0005108748 – Ordinary Share Ticker: BOMI
ISIN Convertible Bond Code: IT0005114480 – Convertible Bond Ticker: BOMI20

For further information.

• **Bomi Italia S.p.A.** •

Investor Relations
tel: +3903962781313
e.mail: investorrelator@bomigroup.com

• **BPER Banca S.p.A.** •

Nominated Adviser
tel: +390512756537
e.mail: bomi@bper.it

